Childhood Arthritis and Rheumatology Research Alliance Hosts Annual Scientific Meeting in Toronto
Working together to advance science to improve outcomes for children living with rheumatic diseases
ATLANTA, April 13, 2016 – The annual scientific meeting of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) opens today in Toronto and over the next five days will draw more than 430 physicians, nurses, parents, patients, and representatives from advocacy organizations in an effort to develop, design and operationalize specific research projects that answer important questions about pediatric rheumatic diseases. The Arthritis Foundation, Novartis Pharmaceuticals and Swedish Orphan Biovitrum AB (Sobi) are key financial supporters of the meeting.
"This meeting brings together pediatric rheumatologists, scientists, nurses, study coordinators and families and patients affected by pediatric rheumatic diseases to formulate research plans and projects to gather data, evaluate treatment and improve outcomes,” says CARRA President, Laura Schanberg, MD, professor at Duke University. “We are pleased to include pediatric residents considering rheumatology as a subspecialty, and are excited about the increased participation of parents and patients, reflecting their growing role in the development and conduct of clinical research."
CARRA’s annual working meeting offers attendees the opportunity to work together to discuss specific diseases and prioritize research agendas. Through this meeting, CARRA members collaborate scientifically and clinically to plan research aimed at improving outcomes in pediatric rheumatic diseases. Attendees divide into workgroups and delve deeply into pressing scientific questions and apply their skills and expertise to finding answers at basic, translational, and clinical research levels, which will transform patient care and outcomes.
The Arthritis Foundation has committed more than $23.5 million to a 5-year partnership with CARRA that supports the CARRA Registry, a long-term database of children with JIA and other pediatric rheumatic diseases, as well as translational research, and small investigational grants aimed at improving outcomes in children with these diseases.
This year’s CARRA 2016 annual meeting is the largest in its 12-year history. The meeting features posters representing the work of more than 150 investigators, speakers focused on various aspects of pediatric rheumatic disease research and meetings for early investigators, fellows, parents and patients, CARRA Registry (NCT02418442) and STOP-JIA (NCT02593006) investigators and study coordinators.
CARRA is an organization of more than 440 pediatric rheumatologists, researchers and research coordinators and includes 95 percent of all pediatric rheumatologists/sites in North America. Founded in in 2002, CARRA operates as a nonprofit, 501c3 organization. CARRA has partnered with the Arthritis Foundation (www.arthritis.org) to align their scientific agendas and expand research in the fight against juvenile arthritis and other pediatric rheumatic disease. See carragroup.org for more information.
About the Arthritis Foundation
The Arthritis Foundation is the Champion of Yes. Leading the fight for the arthritis community, the Foundation helps conquer everyday battles through life-changing information and resources, access to optimal care, advancements in science and community connections. The Arthritis Foundation’s goal is to chart a winning course, guiding families in developing personalized plans for living a full life – and making each day another stride towards a cure. The Foundation also publishes Arthritis Today, the award-winning magazine that reaches 4 million readers per issue.